Basic Information
AxeroVision was founded in 2016 to develop new therapies for ocular inflammatory diseases, such as Dry Eye Disease (DED) and Meibomian Gland Dysfunction (MGD). AXR-159 is under development for the treatment of chronic DED. AXR-270 is being developed for short-term treatment of DED. Both assets have achieved clinical proof-of-concept.
AxeroVision, Inc.
California,United States of America
unclear
--
--